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Objectives The purpose of this study was to determine among community patients with heart failure (HF) whether pulmo-
nary artery systolic pressure (PASP) assessed by Doppler echocardiography was associated with death and im-
proved risk prediction over established factors, using the integrated discrimination improvement and net reclas-
sification improvement.
Background Although several studies have focused on idiopathic pulmonary arterial hypertension, less is known about pul-
monary hypertension among patients with HF, particularly about its prognostic value in the community.
Methods Between 2003 and 2010, Olmsted County residents with HF prospectively underwent assessment of ejection
fraction, diastolic function, and PASP by Doppler echocardiography.
Results PASP was recorded in 1,049 of 1,153 patients (mean age 76  13; 51% women). Median PASP was 48 mm Hg
(25th to 75th percentile: 37.0 to 58.0). There were 489 deaths after a follow-up of 2.7  1.9 years. There was a
strong positive graded association between PASP and mortality. Increasing PASP was associated with an in-
creased risk of death (hazard ratio [HR]: 1.45, 95% confidence interval [CI]: 1.13 to 1.85 for tertile 2; HR: 2.07,
95% CI: 1.62 to 2.64 for tertile 3 vs. tertile 1), independently of age, sex, comorbidities, ejection fraction, and
diastolic function. Adding PASP to models including these clinical characteristics resulted in an increase in the
c-statistic from 0.704 to 0.742 (p  0.007), an integrated discrimination improvement gain of 4.2% (p  0.001),
and a net reclassification improvement of 14.1% (p  0.002), indicating that PASP improved prediction of death
over traditional prognostic factors. All results were similar for cardiovascular death.
Conclusions Among community patients with HF, PASP strongly predicts death and provides incremental and clinically rele-
vant prognostic information independently of known predictors of outcomes. (J Am Coll Cardiol 2012;59:
222–31) © 2012 by the American College of Cardiology FoundationPulmonary hypertension (PH) is prevalent among patients
with heart failure (HF), among both those with reduced
and with preserved left ventricular ejection fraction (EF)
(1–3), with HF being 1 of the most common causes of PH
(4,5). Although there are substantial data on the rare
idiopathic pulmonary arterial hypertension, less is known
about the predictive value of pulmonary pressures in the
more common PH associated with HF (4,6). Some studies
indicate that PH portends a poor prognosis among patients
with HF (1–3,7–11), but have notable limitations including
retrospective design and limitation to prevalent cases and to
subgroups of patients such as advanced HF and reduced or
preserved EF. Further, chronic obstructive pulmonary dis-
ease (COPD) was often excluded, diastolic function was
seldom assessed, and most studies included highly selected
patients from echocardiographic or catheterization series or
referrals to HF clinics. The only population-based study
published thus far was limited to patients with preserved EF
(3); therefore, the prevalence, clinical characteristics, and
prognosis of PH among all community patients with HF
remains uncertain. Further, publications focused chiefly on
all-cause death, and information on the impact of PH on
cardiovascular death is limited.
With the present population-based study, we addressed
these gaps in knowledge by prospectively investigating all
in-patients and out-patients presenting with HF in Olm-
sted County. We aimed to examine the prevalence and
prognostic role of PH estimated by pulmonary arterysystolic pressure (PASP) from Doppler echocardiography,
which is currently considered the best screening method for
PH (6). We tested whether the associations were indepen-
dent of other predictors such as EF and diastolic function,
and investigated whether PASP improved risk prediction
over established prognostic factors using the c-statistic,
integrated discrimination improvement (IDI) and net re-
classification improvement (NRI).
See page 232
Methods
The Rochester Epidemiology Project. This study was
conducted in Olmsted County, Minnesota, and the meth-
ods are analogous to our previously published study of
systolic and diastolic HF (12). Population-based epidemi-
ological research is feasible in Olmsted County because it is
relatively isolated from other urban centers, and only a few
providers (chiefly, Mayo Clinic and Olmsted Medical Cen-
ter) deliver nearly all health care to local residents. Each
provider uses a medical record that captures information for
all encounters and can be easily retrieved. These records are
indexed through the Rochester Epidemiology Project, re-
sulting in the linkage of medical records from all sources of
care (13).
Identification of patients. As previously described, natural
language processing of the unstructured text of the elec-
tronic medical record was used to prospectively identify pa-
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ings compatible with HF (12,14).
After real-time case identifica-
tion, subjects were immediately
contacted to participate in the
prospective study that included
Doppler echocardiography and
venous blood draw for brain na-
triuretic peptide (BNP). If a clin-
ical echocardiogram was not
scheduled within 1 day of the
enrollment, it was scheduled by
the research team with experi-
enced research sonographers per-
forming the examinations under
quality control similar to that in
place for clinical examinations.
Therefore, there was no differ-
ence between examinations per-
formed under clinical or research
auspices. The complete records
of potential cases were manually
reviewed to verify the diagnosis
of HF using both clinical and Framingham criteria (15) and
o collect clinical data. The feasibility and reliability of the
ramingham criteria to ascertain HF in Olmsted County
ave been previously published (16).
Participants provided written consent, and the study was
pproved by the Mayo Clinic institutional review board.
chocardiography Doppler. In Olmsted County, all
chocardiograms are performed and interpreted in the
ayo Clinic Echocardiographic Laboratory. M-mode,
-dimensional, Doppler, and Doppler tissue imaging were
erformed according to guidelines of the American Society
f Echocardiography (17). Digital echocardiographic data
ontaining a minimum of 3 consecutive beats (5 in atrial
brillation) were acquired and transferred to a Mayo Clinic
nstitutional server for storage and archiving. Left ventric-
lar EF was measured by M-mode or 2-dimensional echo-
ardiography using the Quinones formula from the para-
ternal views (18), by the quantitative 2-dimensional biplane
olumetric Simpson method from 4- and 2-chamber views
17), and by the semiquantitative 2-dimensional visual
stimate method from multiple echocardiographic views.
ll methods have been previously validated (18). The EF
alues were averaged when multiple measurements were
erformed. As recommended (19), preserved systolic func-
ion was defined as an EF 50%. Left ventricular end-
iastolic diameter and interventricular septal and posterior
all thickness were measured by M-mode or 2-dimensional
chocardiography from the parasternal views at end diastole
s recommended by the American Society of Echocardiog-
aphy, and they were used to calculate left ventricular mass,
hich was indexed to body surface area (17).
As PASP is equal to right ventricular systolic pressure in
Abbreviations
and Acronyms
BMI  body mass index
BNP  brain natriuretic
peptide
CI  confidence interval
COPD  chronic
obstructive pulmonary
disease
EF  ejection fraction
HF  heart failure
HR  hazard ratio
IDI  integrated
discrimination improvement
MI  myocardial infarction
NRI  net reclassification
improvement
PASP  pulmonary artery
systolic pressure
PH  pulmonary
hypertensionhe absence of pulmonary stenosis, PASP was estimatedsing Doppler echocardiography by calculating the right
entricular to right atrial pressure gradient during systole,
pproximated by the modified Bernoulli equation as 4v2,
here v is the velocity of the tricuspid regurgitation jet in
/s. Right atrial pressure, estimated on the basis of echo-
ardiographic characteristics of the inferior vena cava and
ssigned a standardized value (20), was then added to the
alculated gradient to give PASP (3). Although the agree-
ent between echocardiographic estimates of PASP and
nvasively measured values on right-side heart catheteriza-
ion is suboptimal (21), especially among patients with lung
isease (22), these 2 methods are sufficiently correlated (20)
o warrant the use of Doppler to screen for PH (21,23).
Diastolic function was assessed as previously published
12,24). It integrates Doppler measurements of the mitral
nflow and Doppler tissue imaging of the mitral annulus
25), a sensitive and relatively load-independent measure of
eft ventricular relaxation (12,25,26). The algorithm relies
n mitral inflow and Doppler tissue imaging, both methods
hat can be applied to large numbers of patients with high
eproducibility (25). This approach enabled classifying dia-
tolic function into 4 categories: normal, mild (impaired
elaxation without evidence of increased filling pressures),
oderate (impaired relaxation or pseudonormal with mod-
rate elevation of filling pressures), and severe (advanced
eduction in compliance) (12,25). Diastolic function was
ategorized as indeterminate in the presence of missing
ata.
atient characteristics. The characteristics at the time of
F diagnosis were collected from the medical records.
ubjects were classified as out-patient cases if not hospital-
zed within 7 days of the out-patient diagnosis. Clinicians’
iagnoses were used to identify COPD, atrial fibrillation
nd flutter, hyperlipidemia, hypertension, and current
moking. Diabetes mellitus was defined according to the
merican Diabetes Association criteria (27). The hemoglo-
in value closest to HF diagnosis (1 year) was used to
efine anemia (hemoglobin concentration 13.0 g/dl in
en and 12.0 g/dl in women) (28). Body mass index
BMI [kg/m2]) was calculated using height (first available
out-patient value) and weight (last out-patient value before
HF diagnosis).
Myocardial infarction (MI) was defined by published
criteria (29), and comorbidity was measured by the Charl-
son index, excluding COPD (30). Estimated glomerular
filtration rate was calculated using the last serum creatinine
value before the diagnosis of HF or the first value post-HF
diagnosis (1 year), with the MDRD (Modification of Diet
in Renal Disease) study equation (31).
Serum samples were stored at 70° C until laboratory
testing was performed. The BNP was measured by a 2-site
immunoenzymatic sandwich assay on the DxI 800 auto-
mated immunoassay system (Beckman Instruments,
Chaska, Minnesota). Tests were performed in the Immu-
nochemical Core Laboratory of Mayo Clinic, Rochester,
Minnesota.
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January 17, 2012:222–31 Pulmonary Pressures and Heart FailureFollow-up for death relied on death certificates filed in
Olmsted County, autopsy reports, obituary notices, and
electronic files of death certificates obtained from the
State of Minnesota Department of Vital and Health
Statistics. Cardiovascular cause of death was based on
codes from the 10th version of the International Classi-
fication of Diseases (ICD-10), while relying on the
American Heart Association categories for cardiovascular
deaths (I00 to I99) (32).
Statistical analysis. Data are presented as frequencies and
ercentages for categorical variables, mean  SD for nor-
mally distributed continuous variables, or median (25th to
75th percentiles) for continuous variables with a skewed
distribution. Trends in characteristics across groups were
tested with Mantel-Haenszel chi-square for categorical
variables and linear regression for continuous variables.
Trends in skewed variables were analyzed after logarithmic
transformation. PASP was categorized into tertiles and
coded as a single 3-level variable.
Survival was analyzed with the Kaplan-Meier method
according to PASP tertiles and was compared by the
log-rank test. Cox proportional hazards regression was used
to examine the association between PASP and all-cause
death and cardiovascular (CV)-specific death, univariately
and while controlling for baseline characteristics. Covariate
data were missing in 1% of the patients. The proportional
hazard assumption was tested using the Schoenfeld residuals
and was found to be valid.
To determine whether PASP offered value in predicting
1-year mortality beyond traditional risk indicators, the
incremental value of PASP was assessed using the
c-statistic, IDI, and NRI. It is recognized that reporting a
significant association between a predictor and outcome is
not sufficient to demonstrate value in risk prediction (33). It
is suggested that the c-statistic not be the sole determinant
of clinical utility and that measures of risk discrimination
(IDI) and reclassification (NRI) be used to evaluate the
value of a risk indicator (33).
The IDI measures the change in the difference in the
mean predicted probabilities of death between subjects dead
and alive at 1 year after inclusion of PASP in the base
model. Our base model included the covariates in our final
Cox proportional hazards regression model (age, sex, inci-
dent HF status, comorbidity index, anemia, EF, diastolic
function, and COPD). PASP was log-transformed and
modeled continuously.
The NRI measures improvement in risk classification
using event-specific reclassification tables. Logistic regres-
sion was used to determine the predicted probabilities for
1-year all-cause mortality for each patient using the base
model. The probabilities were then ranked and categorized
into tertiles (13%, 13% to 23%, and 23%). Patients
were reclassified according to the 1-year predicted proba-
bilities of death after addition of PASP into the model. The
NRI quantified the net improvement in risk reclassification
(higher predicted probability of death in subjects dead at 1year, lower predicted probability of death in subjects alive at
1 year). Similar methods were used to determine the NRI
for 1-year CV-specific mortality. The tertile cutpoints for
predicted probability of CV death were 6%, 6% to 12%,
and 12%.
All statistical tests were 2-sided, and a p value of 0.05
was selected for the threshold of statistical significance.
Analyses were performed using SAS statistical software,
version 9.2 (SAS Institute, Cary, North Carolina) and
Splus statistical software, version 8 (TIBCO Software,
Palo Alto, California).
Results
Patient identification and characteristics. Between Sep-
tember 4, 2003, and June 30, 2010, 8,460 Olmsted County
residents were identified from the electronic medical record
as potential candidates for inclusion. After manual record
review, 1,938 patients with active HF (both incident and
prevalent) were approached for participation. Among these,
1,300 consented (participation rate of 67.1%), and 1,153
underwent echocardiography at a median of 1 day (25th to
75th percentile: 0 to 3 days) within the diagnosis of HF.
PASP could not be measured for 104 patients, resulting in
a final study population of 1,049.
The mean age of study subjects was 76  13 years; 1,016
(96.9%) met Framingham criteria for HF; and 51% were
women. The burden of comorbidity was high in this
population as 572 (54.5%) of the subjects presented with a
modified Charlson comorbidity index of 3 or greater.
Among the 1,049 study subjects, 282 (27%) were diagnosed
in the out-patient setting, and 767 (73%) were in-patients;
538 (51%) were incident HF cases, and the remaining 511
(49%) were prevalent cases.
Pulmonary artery systolic pressure. The median PASP
was 48 mm Hg (25th to 75th percentile: 37.0 to 58.0).
When the upper limit of pulmonary pressure was defined as
35 mm Hg, only 21% of patients in this cohort had normal
pulmonary pressures. Baseline characteristics were examined
according to the tertiles of the distribution of PASP,
defined as 41, 41 to 54, and 54 mm Hg (Table 1).
Among patients with PASP 41 mm Hg, 64.4% had
normal PASP (defined as 35 mm Hg).
Patients with higher PASP were more likely to be older,
female, have anemia, atrial fibrillation, lower creatinine
clearance and BMI, and higher New York Heart Associa-
tion functional class and BNP level, while they were less
likely to have hyperlipidemia (Table 1). Increasing PASP
was associated with larger left atrial volume index, higher
ratio of early transmitral flow velocity to early mitral annular
(medial) diastolic velocity (E/e’ ratio) and worse diastolic
function; however, PASP was not associated with left
ventricular mass index, EF, or left ventricular end-diastolic
diameter (Table 2).
Mortality. After a mean follow-up of 2.7  1.9 years, 489
patients died. There was a strong positive graded association
y disea
Y
o
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0.001) (Fig. 1). One-year mortality estimates for patients in
tertiles 1, 2, and 3 were 8%, 19%, and 28%, respectively.
Compared to patients in the lowest PASP tertile, patients in
the middle tertile had an unadjusted 72% increased risk of
death (hazard ratio [HR]: 1.72, 95% confidence interval
[CI]: 1.35 to 2.18) (Fig. 2), whereas patients in the highest
tertile had 2.5 times increased risk of death (HR: 2.64,
Clinical Characteristics of Patients With HF in Olmsted CountyTable 1 Clinical Characteristics of Patients With HF in Olmsted
No.
Missing
Total
(n  1,049)
Age, yrs — 75.6 13.3
Men — 517 (49.3)
Cardiovascular risk factors
Hypertension — 897 (85.5)
Current smoker — 97 (9.3)
Diabetes mellitus — 347 (33.1)
Hyperlipidemia — 783 (74.6)
BMI, kg/m2 — 27.5 (24–32)
Comorbidities
Prior MI — 251 (23.9)
COPD — 293 (27.9)
Estimated GFR, ml/min per 1.73 m2 203 52.2 (38–64)
Anemia 4 537 (51.4)
Atrial fibrillation/flutter 1 379 (36.2)
Comorbidity index —
0 156 (14.9)
1–2 321 (30.6)
3 572 (54.5)
HF characteristics and severity indices
NYHA functional class —
I 63 (6.0)
II or III 647 (61.7)
IV 339 (32.3)
BNP, pg/ml 154 426 (209–836)
Values are mean  SD, n (%), or median (25th to 75th percentile).
BMI  body mass index; BNP  brain natriuretic peptide; COPD  chronic obstructive pulmonar
ork Heart Association; PASP  pulmonary artery systolic pressure.
Echocardiographic Characteristics of Patients With HF in OlmstedTable 2 Echocardiographic Characteristics of Patients With HF
No.
Missing
Total
(n  1,049)
T
PASP
(n
LV mass index, g/m2 401 113 (91–137) 112
LVEDD, mm 46 51 (46–57) 50
LA volume index, ml/m2 586 47 (38–58) 43
E/e’ ratio 152 18 (13–25) 15
EF, % 2 47.6 16.5 48
Diastolic function
Normal 72 (6.9) 25
Mild 49 (4.7) 23
Moderate 618 (58.9) 223
Severe 183 (17.5) 42
Indeterminate 127 (12.1) 30
Values are median (25th to 75th quartile), mean  SD, or n (%).
E/e’ ratio of early transmitral flow velocity to early mitral annular (medial) diastolic velocity; EF ejec
ther abbreviations as in Table 1.95% CI: 2.09 to 3.33). Adjustment for age and sex and
further adjustment for incident HF status, comorbidity
index, anemia, EF, diastolic function, and COPD attenu-
ated these results, although in the final multivariable model,
patients in the middle PASP tertile still had a 45% increased
risk of death (HR: 1.45, 95% CI: 1.13 to 1.85), whereas
patients in the highest tertile were more than twice as likely
to die compared to patients in the lowest tertile (HR: 2.07,
nty
ertile 1
<41 mm Hg
 343)
Tertile 2
PASP 41–54 mm Hg
(n  370)
Tertile 3
PASP >54 mm Hg
(n  336) p Value
.4 13.4 76.2 13.0 77.1 13.3 0.001
(54.8) 172 (46.5) 157 (46.7) 0.035
(85.7) 311 (84.1) 292 (86.9) 0.664
(10.8) 32 (8.7) 28 (8.3) 0.269
(32.9) 110 (29.7) 124 (36.9) 0.278
(79.9) 269 (72.7) 240 (71.4) 0.011
(25–32) 27.5 (24–31) 26.5 (23–31) 0.015
(24.2) 86 (23.2) 82 (24.4) 0.952
(26.0) 110 (29.7) 94 (28.0) 0.552
(44–67) 52.1 (39–64) 48.1 (34–59) 0.001
(42.7) 189 (51.4) 202 (60.3) 0.001
(28.6) 155 (42) 126 (37.5) 0.015
0.096
(16.9) 52 (14.1) 46 (13.7)
(30.9) 121 (32.7) 94 (28.0)
(52.2) 197 (53.2) 196 (58.3)
0.001
(8.5) 16 (4.3) 18 (5.4)
(64.7) 234 (63.2) 191 (56.9)
(26.8) 120 (32.4) 127 (37.8)
(133–566) 417 (233–736) 675 (320–1,170) 0.001
se; GFR  glomerular filtration rate; HF  heart failure; MI myocardial infarction; NYHA  New
tylmsted County
1
m Hg
3)
Tertile 2
PASP 41–54 mm Hg
(n  370)
Tertile 3
PASP >54 mm Hg
(n  336)
p Value
(Trend)
36) 114 (92–135) 115 (91–140) 0.729
7) 51.3 (46–57) 51 (46–57) 0.697
4) 48 (38–61) 50.5 (41–59) 0.001
0) 18 (13–25) 20 (15–30) 0.001
5.5 47.3  17.1 47.6  16.9 0.654
0.001
29 (7.8) 18 (5.4)
16 (4.3) 10 (3.0)
) 218 (58.9) 177 (52.7)
) 64 (17.3) 77 (22.9)
43 (11.6) 54 (16.1)Cou
T
PASP
(n
73
188
294
37
113
274
28.4
83
89
54.2
146
98
58
106
179
29
222
92
306Counin O
ertile
<41 m
 34
(90–1
(46–5
(34–5
(11–2
.1  1
(7.3)
(6.7)
(65.0
(12.2
(8.7)tion fraction; LA left atrial; LV left ventricular; LVEDD left ventricular end-diastolic diameter;
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PASP was not significant (p  0.357), nor was the
nteraction between diastolic function and PASP (p 
.589).
We could not obtain cause of death for 74 patients; thus,
hey were excluded from CV-specific death analyses. Dur-
ng follow-up, 218 patients died of CV death. There was a
imilar graded association between PASP and risk of CV-
pecific death. (p  0.001) (Fig. 3). One-year mortality
stimates for patients in tertiles 1, 2, and 3 were 4%, 10%,
nd 17%, respectively. Patients in the middle PASP tertile
Figure 1 Overall Survival by PASP Tertiles
Among HF Patients
Overall survival by pulmonary artery systolic pressure (PASP) tertiles among
heart failure (HF) patients, n  1,049 (p  0.001). Solid line  PASP tertile 1
(41 mm Hg); dashed line  PASP tertile 2 (41 to 54 mm Hg); and dotted
line  PASP tertile 3 (54 mm Hg).
Figure 2 Association Between PASP Tertiles and All-Cause Mo
The unadjusted and adjusted hazard ratios (HRs) for risk of all-cause mortality usi
sex, incident HF status, comorbidity index, anemia, ejection fraction, diastolic func
monary artery systolic pressure.ad an unadjusted twofold increased risk of CV death (HR:
.22, 95% CI: 1.50 to 3.27) (Fig. 4) compared to patients in
he lowest tertile, and patients in the highest tertile had
early a 4-fold increased risk of CV death (HR: 3.79, 95%
I: 2.60 to 5.53). After adjustment for the same covariates
s in the all-cause death analysis, patients in the middle
ertile still had an 75% increased risk of CV death (HR:
.75, 95% CI: 1.17 to 2.60) whereas patients in the highest
ertile were 2.5 times as likely to die of CV death compared
o patients in the lowest tertile (HR: 2.50, 95% CI: 1.69 to
.71). There was not a significant interaction between EF
y
proportional hazards regression. *Adjusted for age and sex. **Adjusted for age,
nd chronic obstructive pulmonary disease. CI  confidence interval; PASP  pul-
Figure 3 Survival From Cardiovascular Death by
PASP Tertiles Among HF Patients
Survival from cardiovascular death by PASP tertiles among HF patients,
n  975 (p  0.001). Solid line  PASP tertile 1 (41 mm Hg); dashed line 
PASP tertile 2 (41 to 54 mm Hg); and dotted line  PASP tertile 3 (54 mm Hg).
Abbreviations as in Figure 1.rtalit
ng Cox
tion, a
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Pulmonary Pressures and Heart Failure January 17, 2012:222–31and PASP (p 0.079) or diastolic function and PASP (p
0.201).
Impact of PASP on risk prediction. The addition of
PASP to a prognostic model including age, sex, incident
HF status, comorbidity index, anemia, EF, diastolic func-
tion, and COPD resulted in an increase in the c-statistic
from 0.704 to 0.742 (p  0.007), an IDI gain of 4.2% (p 
0.001), and an NRI of 14.1% (p  0.002) (Table 3),
indicating that PASP offered additional value in predicting
1-year all-cause mortality over traditional prognostic factors.
Similar results were found when predicting 1-year CV
mortality. After the addition of PASP, the c-statistic
increased from 0.720 to 0.765 (p 0.020), there was an IDI
Reclassification of Participants by 1-YearAll-C u e Mortality Status Using Model With PASPTable 3 Reclassificat on of Particip nts by 1-YearAll-Cause Mortality Status Using Model With PASP
Model With Established
Risk Factors*
Model With Established
Risk Factors and PASP
<13% Risk 13%–<23% Risk >23% Risk
Participants dead at 1 yr
(n  190)
13% risk 14 8 3
13% to 23% risk 8 22 25
23% risk 5 14 91
Participants alive at 1 yr
(n  781)
13% risk 247 36 3
13% to 23% risk 103 121 47
23% risk 10 46 168
*Established risk factors include age, sex, incident heart failure status, comorbidity index, anemia,
Figure 4 Association Between PASP Tertiles and CV Mortality
The unadjusted and adjusted HRs for risk of cardiovascular (CV) mortality using Co
sex, incident HF status, comorbidity index, anemia, ejection fraction, diastolic funcejection fraction, diastolic function, and chronic obstructive pulmonary disease.
PASP  pulmonary artery systolic pressure.gain of 3.6% (p 0.001), and an NRI of 13.5% (p 0.025)
(Table 4).
Sensitivity analyses. Several ancillary analyses were con-
ducted to assess the robustness of our results. The distribu-
tion of PASP was similar when restricted to incident cases
of HF, to patients meeting Framingham criteria, or to
patients presenting in the out-patient setting.
Analyses in the subset of patients without COPD (n 
756; 72%) yielded similar results for all-cause and CV death,
as did analyses in the subset of patients without atrial
fibrillation (n  669; 64%). Furthermore, results were
similar when analyses were restricted to the subset of
patients with an EF 45% (n  424; 40%).
Reclassification of Participants by 1-YearCardiovas ular Mort li y St tus Using ModelWith PASP
Table 4
Reclassification of Particip nts by 1-Year
Cardiovascular Mortality Status Using Model
With PASP
Model With Established
Risk Factors*
Model With Established
Risk Factors and PASP
<6% Risk 6%–<12% Risk >12% Risk
Participants dead at 1 yr (n  90)
6% risk 6 0 2
6% to 13% risk 7 9 12
13% risk 1 4 49
Participants alive at 1 yr (n  781)
6% risk 256 34 2
6% to 13% risk 104 94 52
13% risk 10 62 167
*Established risk factors include age, sex, incident heart failure status, comorbidity index, anemia,
ortional hazards regression. *Adjusted for age and sex. **Adjusted for age,
nd chronic obstructive pulmonary disease. Abbreviations as in Figure 2.x prop
tion, aejection fraction, diastolic function, and chronic obstructive pulmonary disease.
PASP  pulmonary artery systolic pressure.
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atrial fibrillation, New York Heart Association functional
class, smoking status and estimated glomerular filtration
rate yielded similar results, as did adjustment for BNP.
Removing diastolic function from the final model and
adjusting for E/e’ ratio yielded similar results, as did further
adjustment for BNP and left atrial volume.
Survival of patients without measurable PASP (9%) was
not significantly different from that of patients with mea-
surable PASP (log-rank p  0.997).
Discussion
The present data indicate that pulmonary pressures can be
readily assessed by Doppler echocardiography among pa-
tients with HF in the community and that pulmonary
hypertension is overwhelmingly present in this setting.
PASP was a strong and independent predictor of all-cause
death and CV death independently of other known predic-
tors, including diastolic function measures and BNP. Fur-
ther, PASP improved risk prediction over established risk
factors as assessed using novel risk prediction methodology.
Increased pulmonary pressures in HF. Although PASP
increases with age (34) and patients with HF are mostly
elderly, PASP is higher in HF patients than in the general
population (34). The upper limit of normal for PASP is
commonly defined as 35 mm Hg, while varying with age
and BMI (35). Published studies used varying definitions of
PH, which compromises our ability to compare even infor-
mally across studies and with our data (2,8,36,37). However,
among studies that used similar definitions (3,9), the prev-
alence of PH ranged from 46% to 83%. The corresponding
populations were, however, heterogeneous and selected
populations (Table 5). In the present cohort, when PH was
defined as PASP35 mm Hg, PH was prevalent in the vast
majority of subjects (79%).
In addition, EF was similar across the tertiles of PASP,
and the effect of PH on outcome was similar both for
patients with reduced and for patients with preserved EF.
Selected Studies Reporting on PASP in the Literature 2000 to 201Table 5 Selected Studies Reporting on PASP in the Literature
First Author
(Ref. #) n Year Design
Damy (9) 1,380 2001–2008 Consecutive referrals to
HF clinic
Adhyapak (36) 147 2004–2007 Consecutive HF patients with
echocardiography series
Khush (37) 171 2000–2003 Substudy of ESCAPE trial
Kjaergaard (7) 1,022 2001–2004 Substudy of patients screened
for trial (ECHOS)
Grigioni (8) 196 1996–2003 Echocardiographic series
Ghio (2) 377 1992–1998 Consecutive patients referred
for HF management
Lam (3) 244 2003–2005 Community HF patients
Shalaby (11) 270 2004–2005 Echocardiographic series of
HF patients undergoing CRTCRT cardiac resynchronization therapy; ECHOS Echocardiography and Heart Outcome Study; ESCAPE
VSD  left ventricular systolic dysfunction; other abbreviations as in Tables 1 and 2.Therefore, PH was not associated with the severity of
systolic dysfunction. Similar to previous reports (38), in the
present study, PH was associated with left atrial volume
index, diastolic function grade, and left ventricular filling
pressures (E/e’), confirming that patients included had type
II PH according to the World Health Organization classi-
fication, hence, secondary to left-side heart disease and due
chiefly to elevation in left-sided pressures. Sensitivity anal-
yses excluding patients with COPD showed the results were
unchanged and confirm these findings.
PH in HF has been postulated to be the result of the
combination of the passive effect of elevated left ventricular
end-diastolic pressure backward on the pulmonary venous
circulation and an active vasoreactive process of vasocon-
striction and pulmonary arterial remodeling (3,4). Pathol-
ogy studies have shown remodeling changes in the elastic
fibers of the pulmonary arterial wall, intimal fibrosis, and
medial hypertrophy of pulmonary muscular arteries, with
changes that are similar to or greater than those seen in
idiopathic pulmonary arterial hypertension (39).
In the present study, PASP remained a strong predictor
of death and CV death even after adjusting for diastolic
function or E/e’. The statistical independence between
diastolic function and PASP supports the hypothesis that,
beyond the effect of post-capillary increased venous conges-
tion, there is a superimposed active pre-capillary component
of PH and that this plays a role in prognosis. Therefore, PH
appears to be not only a marker of worse HF, but also may
have itself a direct deleterious effect.
Pulmonary pressures and outcomes. Although there are
substantial data on pulmonary pressures in idiopathic pul-
monary arterial hypertension, which is less common (5,6),
much less is known about the more common PH in HF (6).
Indeed, Table 5 summarizes selected published studies,
which consist chiefly of convenience samples of patients
referred to out-patient or in-patient clinics (2,9), to diag-
nostic testing such as echocardiography (8,11,36), or were
subanalyses of clinical trials (7,37). These studies are thus
to 2010
HF Definition EF % With Measured PASP
ical 26% preserved EF (45%);
74% reduced EF
26% of patients with LVSD;
40% no LVSD
ingham criteria Mean EF 39% 100%
ical Only EF 30% 100%
ical 24% preserved EF (50%)
71% reduced EF
38%
ical Mean EF 27% 100%
ical Only EF 35% 100%
ingham criteria Only EF 50% 83%
ical Not measured 79%02000
Clin
Fram
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the inference that can be drawn from them. In addition,
most published studies were limited to patients with severe
HF (8,37) or to patients with reduced EF (2,8,37) or
preserved EF (3) and often did not include the whole
spectrum of HF. Indeed, the only community study on PH
in HF, conducted by our group, was limited to subjects with
preserved EF (3).
The present data address those gaps in knowledge, reflect
the comprehensive experience of a community, and pertain
to the complete spectrum of HF including in- and out-
patients, systolic and diastolic HF, as well as incident and
prevalent cases. In this setting of high clinical relevance, PH
is a strong independent predictor of outcomes as there is a
graded association between the severity of PH and death in
a large community cohort, irrespective of whether the
patient was admitted to the hospital or evaluated as an
out-patient, in primary or in subspecialty care. The novel
risk prediction methodology used herein provides informa-
tion on the value of PH for risk discrimination and
reclassification, 2 measures of the practical value of a risk
indicator (33). As PASP is readily available from echocar-
diographic studies, which are recommended by professional
guidelines for the evaluation of heart failure (40), it can be
btained with no additional burden to the patient and no
dditional cost to provide important incremental prognostic
nformation.
tudy limitations, strengths, and clinical implications.
otential limitations should be acknowledged to facilitate
he interpretation of the results. We did not account for
ight ventricular size and function as this information was
ot universally available. The inferior vena cava size and
ollapse were used to estimate right atrial pressure in a
emiquantitative method, and right atrial pressure was
dded to the transtricuspid gradient (41). The reproducibil-
ty and reliability of Doppler in measuring PASP are lower
han for right-side heart catheterization (23); however, this
tudy could have not been performed using invasive meth-
ds. We recognize that right-side heart catheterization is
he standard to accurately diagnose PH and determine its
everity as well as impact on right ventricular function.
owever, Doppler estimates of PASP have been shown to
ave adequate correlation with invasive measures (42);
herefore, Doppler echocardiography is now considered the
eference screening method to detect PH (6).
PASP could not be measured in 9% of the patients, a
roportion that is much lower than what is usually reported
7,9). However, survival of patients without measurable
ASP was not significantly different from that of patients
ith measurable PASP.
Strengths of this study include the community-based
pproach, which enhances its external validity, and the novel
ase-finding method, which enables rapid identification of
ll cases of HF (12). We captured the complete spectrum of
F by including incident and prevalent systolic and dia-tolic HF cases indentified during both in-patient andut-patient visits. Further, we relied on rigorous validated
oppler echocardiography techniques applied promptly af-
er HF diagnosis.
In aggregate, these data support the concept that PH may
e a central determinant in the outcome of HF and may,
herefore, represent a potential therapeutic target. Further
tudies are warranted to test this hypothesis.
onclusions
n a large community-based prospective cohort of subjects
ith HF, pulmonary pressures can be readily estimated by
oppler echocardiography. Pulmonary hypertension is a
trong and independent predictor of mortality among pa-
ients with HF and provides incremental and clinically
elevant prognostic information independently of known
redictors of outcomes.
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